ClinicalTrials.govrestricted
A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation
ClinicalTrials.gov study NCT01859026. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ShareScore
32/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 12
- Harmonization
- 12
- Access
- 0
- Reuse readiness
- 0
- Engagement
- 8